Page last updated: 2024-11-04

sulfasalazine and Hypertrophy, Left Ventricular

sulfasalazine has been researched along with Hypertrophy, Left Ventricular in 1 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Daïen, CI1
Fesler, P1
du Cailar, G1
Daïen, V1
Mura, T1
Dupuy, AM1
Cristol, JP1
Ribstein, J1
Combe, B1
Morel, J1

Trials

1 trial available for sulfasalazine and Hypertrophy, Left Ventricular

ArticleYear
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:6

    Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Echocardiography; Etanerce

2013